| 000 -LEADER |
|---|
| fixed length control field |
03829nam a22004575i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150238.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
130428s2013 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781461470700 |
|
978-1-4614-7070-0 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
New York, NY : |
| -- |
Springer New York : |
| -- |
Imprint: Springer, |
| -- |
2013. |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Bonavida, Benjamin. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy |
| Medium |
[electronic resource] : |
| Remainder of title |
Targeted Therapies to Reverse Resistance / |
| Statement of responsibility, etc |
edited by Benjamin Bonavida. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XIII, 260 p. 30 illus., 23 illus. in color. |
| Other physical details |
online resource. |
| 440 1# - SERIES STATEMENT/ADDED ENTRY--TITLE |
|---|
| Title |
Resistance to Targeted Anti-Cancer Therapeutics, |
| International Standard Serial Number |
2196-5501 ; |
| Volume number/sequential designation |
1 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface -- Multidrug resistance in cancer: a tale of ABC drug transporters -- Multidrug resistance: a role for membrane physics, pH and drug transporters -- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer -- Mechanisms of resistance to targeted B-Raf therapies -- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer -- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance -- Overcoming drug resistance through elevation of ROS in cancer -- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy -- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways -- Collateral sensitivity in drug-resistant tumor cells -- Human cancer resistance to trail-apoptotic pathway-targeted therapies -- The dark side of apoptosis -- Index. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Drug interactions. |
|
|---|
| Topical term or geographic name as entry element |
Cytology. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
|
|---|
| Topical term or geographic name as entry element |
Cancer Research. |
|
|---|
| Topical term or geographic name as entry element |
Apoptosis. |
|
|---|
| Topical term or geographic name as entry element |
Cell Biology. |
|
|---|
| Topical term or geographic name as entry element |
Drug Resistance. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9781461470694 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-4614-7070-0 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
